August 2012
-
US-based Pneuma Respiratory says that it has developed a digital,soft mist inhaler with an electronic droplet ejector system capable of delivering different droplet sizes. According to the company, the device has been validated by two… Read more . . .
-
Intranasal cannabinoid developer Therapix Biosciences has announced the appointment of its Chairman of the Board Ascher Shmulewitz as interim CEO. In May 2017, the company said that it was looking for a US-based CEO after… Read more . . .
-
Bayer has launched a line of saline nasal sprays for children aged 6 months and older in the US, the company said. The products, which include hydraSense Ultra-Gentle Nasal Mist, hydraSense Nasal Care Single-Use Vials… Read more . . .
-
GSK and Innoviva have published data from a study in which Anoro Ellipta umeclidinium/vilanterol demonstrated superior lung function improvement in COPD patients compared to Stiolto Respimat tiotropium/olodaterol. The data were published in Advances in Therapy… Read more . . .
-
AZTherapies, which is developing an inhaled cromolyn/oral ibuprofen combination therapy for the treatment of Alzheimer’s disease, has appointed former Pfizer executive Karen Reeves as President and Chief Medical Officer. The company’s ALZT-OP1 combination is currently… Read more . . .
-
Theravance Biopharma has opened a corporate office in Dublin, Ireland and plans to hire 30 new employees over the next 2 years, the company said. The company also announced that it and its partner Mylan… Read more . . .
-
Novoteris has announced that Health Canada has okayed a planned Phase 2a clinical trial of the company’s Thiolanox inhaled nitric oxide gas for the treatment of non-tuberculous mycobacteria (NTM) lung infections. The study will enroll… Read more . . .
-
Capsugel has announced the addition of an Xcelodose 600S filling machine for micro-dosing of powders into capsules at its facility in Edinburgh, Scotland. Capsugel was acquired by Lonza earlier this year. The Edinburgh facility’s Site… Read more . . .
-
Cyrano Therapeutics has announced a partnership agreement with Chinese CRO Shanghai Newsummit Biopharma (Newsummit) for development of Cyrano’s intranasal theophylline for the treatment of taste and smell disorders in China. Newsummit will provide development services… Read more . . .
-
Impel NeuroPharma has announced the initiation of a Phase 1 trial of INP104 intranasal dihydroergotamine (DHE), which the company is developing for the treatment of acute migraine headache. The bioavailability study, which is taking place… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.